Linda Stempora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Linda Stempora has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Andrew S. Barbas
Department of Surgery, Duke University Medical Center, Durham, NC, USA
1 shared publication - Brandon Lu
Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
1 shared publication - Eileen Tsai Chambers
Department of Pediatrics and Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC
1 shared publication Emeraghi David
Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
1 shared publication- Haojun Xu
Thomas Lord Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
1 shared publication - Jean Kwun
Duke Transplant Center, Duke University School of Medicine, Durham, NC 27710, USA
1 shared publication
Latest Publications
- Open Access
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (36) , eady3262
Acoustofluidic system for targeted antibody removal in transplantation: Enabling small-volume therapeutic apheresis
Antibody-mediated rejection is a leading cause of allograft failure and mortality in pediatric solid organ transplant recipients. Current apheresis systems require large blood volumes and are primarily designed for adults, making them unsuitable for children and small animals. These systems often indiscriminately remove both harmful and protective antibodies, increasing the risk of complications such as life-threatening infections. To address this critical need, we developed acoustofluidic-based system for targeted antibody removal in transplantation (A-START). A-START is engineered to handle small blood volumes and has demonstrated efficacy in preclinical small animal trials. In a sensitized rodent skin transplantation model, A-START only demands 240 microliters of blood, selectively removing donor-specific alloantibodies (DSAs) while preserving protective antibodies, such as tetanus antibodies. A-START retains ~95% of beneficial antibodies and achieves a 60% improvement in DSA removal compared to conventional methods. These findings highlight the transformative potential of A-START as a promising, reliable, scalable solution for improving outcomes in pediatric transplantation and treating antibody-mediated diseases.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (36) , eady3262
Open AccessAcoustofluidic system for targeted antibody removal in transplantation: Enabling small-volume therapeutic apheresis
Antibody-mediated rejection is a leading cause of allograft failure and mortality in pediatric solid organ transplant recipients. Current apheresis systems require large blood volumes and are primarily designed for adults, making them unsuitable for children and small animals. These systems often indiscriminately remove both harmful and protective antibodies, increasing the risk of complications such as life-threatening infections. To address this critical need, we developed acoustofluidic-based system for targeted antibody removal in transplantation (A-START). A-START is engineered to handle small blood volumes and has demonstrated efficacy in preclinical small animal trials. In a sensitized rodent skin transplantation model, A-START only demands 240 microliters of blood, selectively removing donor-specific alloantibodies (DSAs) while preserving protective antibodies, such as tetanus antibodies. A-START retains ~95% of beneficial antibodies and achieves a 60% improvement in DSA removal compared to conventional methods. These findings highlight the transformative potential of A-START as a promising, reliable, scalable solution for improving outcomes in pediatric transplantation and treating antibody-mediated diseases.